RecruitingHead and Neck Squamous Cell Carcinoma
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To learn if it is effective to use advanced radiation treatment techniques (stereotactic radiation or "SBRT") to safely deliver a strong dose of radiation to your tumor in a shorter period of time than would typically be feasible with traditional methods.
Sponsor: M.D. Anderson Cancer Center
You may qualify if…
- ✓ Age 18 or older
- ✓ Willing to provide informed consent
- ✓ Histologically confirmed squamous cell carcinoma
- ✓ Primary tumor site in the head and neck (includes oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, salivary gland, and cutaneous subsites as well as tumors of unknown primary site)
- ✓ Ineligible for curative intent treatment after multidisciplinary evaluation (including evaluation by radiation oncologist and surgeon followed by presentation at multidisciplinary tumor board prior to randomization)
- ✓ Prior therapy including radiation, surgery, or systemic therapy is permitted unless further radiation is deemed inappropriate by the enrolling physician
- ✓ Metastatic disease is permitted
You may not qualify if…
- ✕ Contraindications to radiotherapy
- ✕ Pregnant or lactating women
- ✕ 5.0 PRE-TREATMENT EVALUATION
- ✕ History and physical examination including laryngopharyngoscopy by a radiation oncologist and/or head and neck surgeon within 8 weeks prior to randomization.
- ✕ o Clinical examination will include a detailed description of disease target including measurement where feasible to facilitate response assessment
- ✕ Documentation of smoking history
- ✕ Staging imaging within 12 weeks prior to randomization:
- ✕ Contrast-enhanced CT of the neck and chest or
Where it's recruiting
Texas
Houston
Source: ClinicalTrials.gov · NCT05674396 · last updated 2026-02-19